• Purity

  >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining

• Endotoxin Level

  <1.0 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to bind biotinylated Pam3CysSerLys4 (PAM3CSK4) (2 μg/mL). The 50% maximum binding is achieved at 0.1‑0.5 μg/mL of Recombinant Human TLR2.

  Results can vary with different preparations of biotinylated PAM3CSK4.
  Optimal dilutions should be determined by each laboratory for each application.

• Source

  Mouse myeloma cell line, NS0-derived Glu21-Leu590, with a C-terminal 10-His tag

• Accession #

• N-terminal Sequence    
  Analysis

  Glu21

• Predicted Molecular Mass

  65.7 kDa

• SDS-PAGE

  75-80 kDa, reducing conditions

Background: TLR2

Human toll-like receptor (TLR) family includes ten members that activate the innate immune response via an ability to recognize molecular structures found in a variety of microbial pathogens (1-3). All TLR family members are type I transmembrane proteins with a large number of extracellular leucine-rich repeats (LRRs) and a cytoplasmic Toll/IL-1 receptor (TIR) domain. Human TLR2 is synthesized as a 784 amino acid precursor (2) that contains a signal sequence (aa 1-18), an extracellular domain (aa 19‑588) with approximately 20 LRRs, a transmembrane segment (aa 589-609), and a cytoplasmic TIR domain (aa 610-784). The receptor is expressed on a number of cell types including monocytes, dendritic cells, neutrophils, B cells endothelial cells, and hepatocytes (1, 2, 4). TLR2 functions as part of a heterodimeric complex with either TLR1 or TLR6, and possibly other co-receptors (1). These complexes recognize lipoproteins and glycolipids from gram-positive and gram-negative bacteria as well as mycoplasma and yeast. TLR2/TLR1 heterodimers bind triacylated lipopeptides, while the TLR2/TLR6 heterodimer preferentially recognizes diacylated lipopeptides (5). Upon ligand recognition, TLR2 delivers an activating signal via the associated adapter molecules, MyD88 and TIRAP (1, 6). TLR2 signaling results in dendritic cell maturation characterized by increased surface expression of class II MHC and the T cell co-stimulators, CD80 and CD86 (1, 2). Activation via TLR2 also results in production of a number of pro‑inflammatory cytokines including TNF-alpha, IL-2, IL-6, IL-12, and MIP-2 (1-3).

• References:

1. Wetzler, L. (2003) Vaccine 21:S2/55.

2. Kirschning, C. and R. Schumann (2002) Curr. Top. microbiol. Immunol. 270:121.

3. Netea, M. et al. (2004) J. Leukoc. Biol. 75:749.

4. Flo T. et al. (2001) J. Leukoc. Biol. 69:474.

5. Akira S. (2003) Curr. Opin. Immunol. 15:5.

6. Yamamoto M. et al. (2002) Nature 420:324.

• Long Name:

  Toll-like Receptor 2

• Entrez Gene IDs:

  7097 (Human); 24088 (Mouse); 310553 (Rat)

• Alternate Names:

  CD282 antigen; CD282; TIL4CD282; TLR2; toll/interleukin 1 receptor-like 4; Toll/interleukin-1 receptor-like protein 4; toll-like receptor 2